Published in J Drug Target on January 01, 2003
Defensins as anti-inflammatory compounds and mucosal adjuvants. Future Microbiol (2010) 0.95
Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin. Gastroenterol Hepatol Bed Bench (2014) 0.77
Effect of Bee Venom and Its Fractions on the Release of Pro-Inflammatory Cytokines in PMA-Differentiated U937 Cells Co-Stimulated with LPS. Vaccines (Basel) (2016) 0.75
Development and initial evaluation of a real-time RT-PCR assay to detect bluetongue virus genome segment 1. J Virol Methods (2007) 1.66
Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev (2005) 1.08
Tissue distribution of radioactivity following intranasal administration of radioactive microspheres. J Pharm Pharmacol (2001) 1.07
Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine (1998) 1.03
Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine (1996) 1.02
Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm (2004) 0.94
Nasal delivery of vaccines. J Drug Target (1996) 0.92
Immunisation against plague by transcutaneous and intradermal application of subunit antigens. Vaccine (2004) 0.91
Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliv Rev (2001) 0.88
Selective biotinylation of Neisseria meningitidis group B capsular polysaccharide and application in an improved ELISA for the detection of specific antibodies. J Immunol Methods (1993) 0.88
Immunological aspects of polymer microsphere vaccine delivery systems. J Drug Target (2003) 0.85
Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine (2001) 0.85
Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J Control Release (2000) 0.84
Encapsulation of plasmid DNA in PLGA-stearylamine microspheres: a comparison of solvent evaporation and spray-drying methods. J Microencapsul (2003) 0.83
Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. Biochem Pharmacol (1985) 0.83
Antimicrobial properties of liposomal polymyxin B. J Antimicrob Chemother (1999) 0.83
Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int J Pharm (2008) 0.83
The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles. Biomaterials (2008) 0.83
Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol (2004) 0.82
Biodegradable microparticles with different release profiles: effect on the immune response after a single administration via intranasal and intramuscular routes. J Pharm Pharmacol (2000) 0.81
Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs. J Pharm Pharmacol (1993) 0.80
Mucosal delivery of herpes simplex virus vaccine. Res Virol (1992) 0.80
Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: studies on the effect of vehicle volume. Int J Pharm (1999) 0.80
Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationic-hydrophilic copolymers. Eur J Pharm Sci (2000) 0.80
Liposomal (MLV) polymyxin B: physicochemical characterization and effect of surface charge and drug association. J Drug Target (1993) 0.79
Role of immunoglobulin G subclasses in Q fever. Eur J Clin Microbiol Infect Dis (1995) 0.79
Protection of the enzyme L-asparaginase during lyophilisation--a molecular modelling approach to predict required level of lyoprotectant. Int J Pharm (1999) 0.79
The prolongation of the in vitro dissolution of a soluble drug (phenethicillin potassium) by microencapsulation with ethyl cellulose. J Pharm Pharmacol (1981) 0.79
Immune responses to V antigen of Yersinia pestis co-encapsulated with IFN-gamma: effect of dose and formulation. Vaccine (1998) 0.79
Autoantibody profiles in the sera of patients with Q fever: characterization of antigens by immunofluorescence, immunoblot and sequence analysis. J Autoimmune Dis (2005) 0.78
Streptococcus equi antigens adsorbed onto surface modified poly-epsilon-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine (2008) 0.78
New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model. Vaccine (2008) 0.78
The preparation of liposomes using compressed carbon dioxide: strategies, important considerations and comparison with conventional techniques. J Pharm Pharmacol (2006) 0.78
The form variation of the capsular polysaccharide K1 is not a critical virulence factor of Escherichia coli in a neonatal mouse model of infection. Microb Pathog (1999) 0.78
Immobilisation of vaccines onto micro-crystals for enhanced thermal stability. Int J Pharm (2005) 0.77
The use of albumin microspheres in the treatment of carrageenan-induced inflammation in the rat. J Pharm Pharmacol (1992) 0.77
Cholesterol-bile salt vesicles as potential delivery vehicles for drug and vaccine delivery. Int J Pharm (2005) 0.76
Dynamics of the murine humoral immune response to Neisseria meningitis group B capsular polysaccharide. Infect Immun (1998) 0.76
Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-gamma or IL-4, but not IL-6. Vaccine (2002) 0.76
Oral plasmid DNA delivery systems for genetic immunisation. J Drug Target (2003) 0.76
Distribution of IgA subclass response to Coxiella burnetii in patients with acute and chronic Q fever. Clin Immunol Immunopathol (1998) 0.76
Intranasal administration of influenza vaccines: current status. BioDrugs (2000) 0.76
Studies on the co-encapsulation, release and integrity of two subunit antigens: rV and rF1 from Yersinia pestis. J Pharm Pharmacol (1999) 0.76
Distribution of immunoglobulin G (IgG) and A (IgA) subclasses following Q fever vaccination with soluble phase I Coxiella burnetii extract. Vaccine (2000) 0.75
Cellular and humoral responses to microencapsulated Yersinia pestis subunit vaccines following oral delivery. Biochem Soc Trans (1997) 0.75
Effect of suspending agents on the bioavailability of suspensions of sulphathiazole. Farmaco Prat (1979) 0.75
Expression and stability of herpes simplex virus antigens in Salmonella typhimurium. Adv Exp Med Biol (1995) 0.75
Oral delivery and fate of poly(lactic acid) microsphere-encapsulated interferon in rats. J Pharm Pharmacol (1997) 0.75
Preparation, properties and the effects of free and liposomal tobramycin on siderophore production by Pseudomonas aeruginosa. J Antimicrob Chemother (1994) 0.75
PDLLA microspheres containing steroids: spray-drying, o/w and w/o/w emulsifications as preparation methods. J Microencapsul (1998) 0.75
Surface modified polymeric nanoparticles for immunisation against equine strangles. Int J Pharm (2009) 0.75
Stimulation of spleen cells in vitro by nanospheric particles containing antigen. J Control Release (2003) 0.75
Analysis of the ontogeny of the murine humoral response to Neisseria meningitidis B capsular polysaccharide reveals levels of complexity relevant to vaccine development. J Infect Dis (2001) 0.75
Poly(lactic acid) microspheres as immunological adjuvants for orally delivered cholera toxin b subunit. Biochem Soc Trans (1992) 0.75
Calorimetric study of bovine serum albumin dilution and adsorption onto polystyrene particles. Int J Pharm (2005) 0.75
The prolongation of the survival times of mice implanted with TLX5 cells by treatment with methotrexate encapsulated in erythrocytes. Biochem Pharmacol (1987) 0.75
Increased resistance of DNA lipoplexes to protein binding in vitro by surface-modification with a multivalent hydrophilic polymer. J Drug Target (2004) 0.75